SERAQUEST VZV IGG— 510(k) K972295

Substantially Equivalent

Quest Intl., Inc.

FDA 510(k) clearance K972295 for SERAQUEST VZV IGG, Substantially Equivalent on 1997-11-05. Applicant: Quest Intl., Inc.. Device class: 2.

Clearance details

Applicant: Quest Intl., Inc.
Product code: Code LFY
Device class: Class 2
Regulation: 21 CFR 866.3900
Advisory panel: Microbiology
Date received: 1997-06-19
Decision date: 1997-11-05
Decision: Substantially Equivalent
Clearance type: Traditional
Location: North Miami, FL, US

Download summary PDF View on FDA.gov ↗

Recent devices under product code LFY

K231214 — LIAISON VZV IgG HT, LIAISON Control VZV IgG HT2023-10-27
K150375 — LIAISON VZV IgG, LIAISON Control VZV IgG2015-03-11
K070317 — ZEUS SCIENTIFIC, INC VZV IGM ELISA TEST SYSTEM2007-07-05
K061820 — DIASORIN LIAISON VZV IGG2007-02-26
K051484 — ZEUS SCIENTIFIC, INC., ATHENA MULTI-LYTE MMRV IGG TEST SYSTEM.2005-12-05

More clearances from Quest Intl., Inc.

K091260 — SERAQUEST EBV EA-D IGG TEST2009-06-08
K033915 — MODIFICATION TO SERAQUEST EB VCA IGG2004-01-16
K033780 — MODIFICATION TO SERAQUEST VCA IGM2004-01-15
K023593 — SERAQUEST ANTI-THYROID PEROXIDASE (TPO)2003-02-06
K023592 — SERAQUEST ANTI-THYROGLOBULIN2003-01-06

Data sourced from openFDA. This site is unofficial and independent of the FDA.